CITN11-02 interim trial results: subcutaneous administration of recombinant human IL-15 (rhIL-15) is associated with expansion of peripheral blood CD56+ NK cells and CD8+ T cells
Journal for ImmunoTherapy of Cancer（2015）
关键词
Dose Limit Toxicity,Cancer Immunotherapy,Absolute Lymphocyte Count,Peripheral Blood CD56,Dose Cohort
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要